Tag: tools

  • Budget

    What is a Budget?

    A budget is a quantitative expression of a plan for a defined period of time. It may include planned sales volumes and revenues, resource quantities, costs and expenses, assets, liabilities and cash flows. It expresses strategic plans of business units, organizations, activities or events in measurable terms.

    Etymology of Budget

    A budget (derived from old French word bougette, purse) is a quantified financial plan for a forthcoming accounting period.

    A budget is an important concept in microeconomics, which uses a budget line to illustrate the trade-offs between two or more goods. In other terms, a budget is an organizational plan stated in monetary terms.

    Purpose of Budget

    Budget helps to aid the planning of actual operations by forcing managers to consider how the conditions might change and what steps should be taken now and by encouraging managers to consider problems before they arise. It also helps co-ordinate the activities of the organization by compelling managers to examine relationships between their own operation and those of other departments. Other essentials of budget include:

        To control resources
        To communicate plans to various responsibility center managers.
        To motivate managers to strive to achieve budget goals.
        To evaluate the performance of managers
        To provide visibility into the company's performance
        For accountability

    In summary, the purpose of budgeting is tools:

        Tools provide a forecast of revenues and expenditures, that is, construct a model of how a business might perform financially if certain strategies, events and plans are carried out.
        Tools enable the actual financial operation of the business to be measured against the forecast.
        Lastly, tools establish the cost constraint for a project, program, or operation.

     

    Views: 0

  • Massive proportion of world’s population are living with herpes infection

    Massive proportion of world’s population are living with herpes infection

    Virus causing genital herpes may put millions of people at greater risk of infection with HIV

    About half a billion people worldwide are living with genital herpes, and several billion have an oral herpes infection, new estimates show.

    Authored by staff at the University of Bristol, World Health Organization (WHO), and Weill Cornell Medical College-Qatar, and published in the Bulletin of the World Health Organization,
    the new study estimates the global infection prevalence and incidence of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) in 2016. 

    “Herpes infection affects millions of people across the globe and can have far-reaching health effects. We need more investment and commitment to develop better treatment and prevention tools for this infection.” says Dr Sami Gottlieb, Medical
    Officer at WHO and an author of the study.

    Prevalence and incidence

    An estimated 491.5 million people were living with HSV-2 infection in 2016, equivalent to 13.2% of the world’s population aged 15 to 49 years. HSV-2 is almost exclusively sexually transmitted, causing infection in the genital or anal area (genital
    herpes).

    An estimated 3.7 billion people had HSV-1 infection during the same year – around 66.6% of the world’s population aged 0 to 49. HSV-1 is mainly transmitted by oral to oral contact to cause infection in or around the mouth (oral herpes). However,
    HSV-1 can also be transmitted to the genital area through oral-genital contact – during oral sex – to cause genital herpes. Most HSV-1 infections were oral; however, between 122 million to 192 million people were estimated to have genital
    HSV-1 infection, depending on the assumptions used in the estimation model.

    Because herpes is a lifelong infection, estimated prevalence increased with age; HSV-2 prevalence was also higher among women and in the WHO African Region.

    Health and social impacts

    Most people living with herpes, caused by either HSV-1 or 2, are unaware they have the infection.

    When symptoms do occur however, oral herpes infection can lead to painful sores around the mouth (“cold sores”). Genital herpes infection can cause recurring, often painful, genital sores, often referred to as genital ulcer disease. 

    WHO and partners published a study in March 2020 estimating that around 5% of the world’s population (187 million people) suffered from at least one episode of herpes-related genital ulcer disease in 2016 (1). Most of these episodes were due to
    HSV-2, which can recur frequently over many years.

    Recurrent symptoms of genital herpes can lead to stigma and psychological distress, and can have an important impact on quality of life and sexual relationships. However, in time, most people with herpes adjust to living with the infection.

    “Genital herpes is a substantial health concern worldwide – beyond the potential pain and discomfort suffered by people living with the infection, the associated social consequences can have a profound effect on sexual and reproductive health”
    says Dr Ian Askew, Director of the Department of Sexual and Reproductive Health and Research at WHO. 

    Herpes and HIV

    A strong association exists between HSV-2 infection and HIV infection. In 2019, WHO commissioned a modeling study to estimate how much HSV-2 infection might contribute to HIV incidence. The study estimated that almost 30% of new sexually acquired HIV
    infections in 2016 worldwide were likely attributable to HSV-2 infection (2). 

    Evidence shows that people with HSV-2 infection are at least three times more likely to become infected with HIV, if exposed. HSV-2 leads to inflammation and small breaks in the genital and anal skin that can make it easier for HIV to cause infection.
    In addition, people with both HIV and HSV-2 infection are more likely to spread HIV to others.

    Women have higher biologic susceptibility to both HSV-2 and HIV. Women living in the WHO Africa Region have the highest HSV-2 prevalence and exposure to HIV – putting them at greatest risk of HIV infection, with negative implications for their health
    and well-being. 

    For people living with HIV (or who are living with other conditions that compromise their immune systems) as well as HSV-2, the symptoms of herpes can be more severe and more frequent. 

    Neonatal herpes

    Neonatal herpes can occur when an infant is exposed to HSV in the genital tract during delivery. This is a rare condition, occurring in an estimated 10 out of every 100,000 births globally, but can lead to lasting neurologic disability or death. The risk
    for neonatal herpes is greatest when a mother acquires HSV infection for the first time in late pregnancy. Women who have genital herpes before they become pregnant are at very low risk of transmitting HSV to their infants.

    No cure – better treatment and prevention needed

    There is no cure for herpes. At present, antiviral medications, such as acyclovir, famciclovir, and valacyclovir, can help to reduce the severity and frequency of symptoms but cannot cure the infection.

    As well as increasing awareness about HSV infection and its symptoms, improved access to antiviral medications and heightened HIV prevention efforts for those with genital HSV symptoms are needed globally. 

    In addition, development of better treatment and prevention interventions is needed, particularly HSV vaccines. WHO and partners are working to accelerate research to develop new strategies for prevention and control of HSV infections. Such research includes
    the development of HSV vaccines and topical microbicides. Several candidate vaccines and microbicides are currently being studied.

    “A vaccine against HSV infection would not only help to promote and protect the health and well-being of millions of people, particularly women, worldwide – it could also potentially have an impact on slowing the spread of HIV, if developed
    and provided alongside other HIV prevention strategies” says Dr Meg Doherty, Director of the WHO Department of Global HIV, Hepatitis, and STI Programmes.

    Related publications

    WHO guidelines for the treatment of Genital Herpes Simplex Virus

    WHO preferred product characteristics for herpes simplex virus vaccines

     

    ———————-

    (1) Looker KJ, Johnston C, Welton NJ, et al. The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study. BMJ Glob Health. 2020;5(3):e001875. doi: 10.1136/bmjgh-2019- 001875.

    (2) Looker KJ, Welton NJ, Sabin KM, et al.Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect Dis.2020;20(2):240-249. doi: 10.1016/S1473-3099(19)30470-0.

    Massive proportion of world’s population are living with herpes infection
    Read More
    https://www.who.int/news-room/detail/01-05-2020-massive-proportion-world-population-living-with-herpes-infection

    Views: 0

  • Global leaders unite to ensure everyone everywhere can access new vaccines, tests and treatments for COVID-19

    Global leaders unite to ensure everyone everywhere can access new vaccines, tests and treatments for COVID-19

    Heads of state and global health leaders today made an unprecedented commitment to work together to accelerate the development and production of new vaccines, tests and treatments for COVID-19 and assure equitable access worldwide.

    The COVID-19 pandemic has already affected more than 2.4 million people, killing over 160,000. It is taking a huge toll on families, societies, health systems and economies around the world, and for as long as this virus threatens any country, the entire world is at risk. 

    There is an urgent need, therefore, while following existing measures to keep people physically distanced and to test and track all contacts of people who test positive, for innovative COVID-19 vaccines, diagnostics and treatments.

    “We will only halt COVID-19 through solidarity,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Countries, health partners, manufacturers, and the private sector must act together and ensure that the fruits of science and research can benefit everybody.”

    Work has already started. Since January, WHO has been working with researchers from hundreds of institutions to develop and test vaccines, standardize assays and standardize regulatory approaches on innovative trial designs and define criteria to prioritize vaccine candidates.  The Organization has prequalified diagnostics that are being used all over the world, and more are in the pipeline. And it is coordinating a global trial to assess the safety and efficacy of four therapeutics against COVID-19.

    The challenge is to speed up and harmonize processes to ensure that once products are deemed safe and effective, they can be brought to the billions of people in the world who need them. Past experience, in the early days of HIV treatment, for example, and in the deployment of vaccines against the H1N1 outbreak in 2009, shows that even when tools are available, they have not been equally available to all.

    So today leaders came together at a virtual event, co-hosted by the World Health Organization, the President of France, the President of the European Commission, and the Bill & Melinda Gates Foundation. The event was joined by the UN Secretary General, the AU Commission Chairperson, the G20 President, heads of state of France, South Africa, Germany, Vietnam, Costa Rica, Italy, Rwanda, Norway, Spain, Malaysia and the UK (represented by the First Secretary of State).

    Health leaders from the Coalition for Epidemic Preparedness Innovations (CEPI), GAVI-the Vaccine Alliance, the Global Fund, UNITAID, the Wellcome Trust, the International Red Cross and Red Crescent Movement (IFRC), the International Federation of Pharmaceutical Manufacturers (IFPMA), the Developing Countries Vaccine Manufacturers’ Network (DCVMN), and the International Generic and Biosimilar Medicines Association (IGBA) committed to come together, guided by a common vision of a planet protected from human suffering and the devastating social and economic consequences of COVID-19, to launch this groundbreaking collaboration. They are joined by two Special Envoys:  Ngozi Okonjo-Iweala, Gavi Board Chair and Sir Andrew Witty, former CEO of GlaxoSmithKline.

    They pledged to work towards equitable global access based on an unprecedented level of partnership. They agreed to create a strong unified voice, to build on past experience and to be accountable to the world, to communities and to one another.

    “Our shared commitment is to ensure all people have access to all the tools to prevent, detect, treat and defeat COVID-19,” said Dr Tedros. “No country and no organization can do this alone. The Access to COVID-19 Tools Accelerator brings together the combined power of several organizations to work with speed and scale.”

    Health leaders called on the global community and political leaders to support this landmark collaboration and for donors to provide the necessary resources to accelerate achievement of its objectives, capitalizing on the opportunity provided by a forthcoming pledging initiative that starts on 4 May 2020. This initiative, spearheaded by the European Union, aims to mobilize the significant resources needed to accelerate the work towards protecting the world from COVID-19.

     

    Global leaders unite to ensure everyone everywhere can access new vaccines, tests and treatments for COVID-19
    Read More
    https://www.who.int/news-room/detail/24-04-2020-global-leaders-unite-to-ensure-everyone-everywhere-can-access-new-vaccines-tests-and-treatments-for-covid-19

    Views: 0

  • Commitment and call to action: Global collaboration to accelerate new COVID-19 health technologies

    Commitment and call to action: Global collaboration to accelerate new COVID-19 health technologies

    Our Vision and Mission

    Grounded in a vision of a planet protected from human suffering
    and the devastating social and economic consequences of
    COVID-19, we, an initial group of global health actors (BMGF,
    CEPI, Gavi, Global Fund, UNITAID, Wellcome Trust, WHO) and
    private sector partners and other stakeholders, are launching
    a landmark, global and time-limited collaboration to accelerate the
    development, production and equitable global access to new COVID-19 essential health technologies.

    We know that as long as anyone is at risk from this virus, the entire
    world is at risk – every single person on the planet needs to be
    protected from this disease.

    We agree that alongside evidence-based public health measures,
    innovative COVID-19 diagnostics, therapeutics and vaccines are
    needed – in record time and at record scale and access – to save
    millions of lives and countless trillions of dollars, and to return
    the world to a sense of ‘normalcy’.

    We recognize the significant amount of critical work, investment
    and initiatives already ongoing around the world to expedite
    the development and deployment of innovative COVID-19 related
    products and interventions.

    We appreciate that while development and deployment of
    innovative products is essential, it will not be enough. We must
    simultaneously and urgently accelerate the strengthening of
    sustainable health systems and capacities to enable delivery of
    the new COVID-19 tools to those who need them and to mitigate
    the knock-on impact on other diseases.

    We remember lessons from the past, which have shown that even
    when effective tools are available to the world, too often some
    are protected, while others are not. This inequity is unacceptable –
    all tools to address COVID-19 must be available to all. In the fight
    against COVID-19, no one should be left behind.

    We understand we cannot do this alone, and that we need to
    work together in unprecedented and inclusive partnership with all
    stakeholders – political leaders, public and private sector partners,
    civil society, academia, and all other stakeholders across society
    – jointly leveraging our comparative strengths and respective
    voices to drive towards collective solutions, an accelerated path,
    and access for all. We are stronger, faster and more effective
    working together.

    Our Mission is not only accelerated development and availability
    of new COVID-19 tools – it is to accelerate equitable global access
    to safe, quality, effective, and affordable COVID-19 diagnostics,
    therapeutics and vaccines, and thus to ensure that in the fight
    against COVID-19, no one is left behind.

    Our Commitment

    1. We commit to the shared aim of equitable global
      access to innovative tools for COVID-19 for all.
    2. We commit to an unprecedented level of partnership
      – proactively engaging stakeholders, aligning and
      coordinating efforts, building on existing collaborations, collectively devising solutions, and grounding
      our partnership in transparency, and science.
    3. We commit to create a strong unified voice to
      maximize impact, recognizing this is not about
      singular decision-making authority, but rather
      collective problem-solving, interconnectedness and
      inclusivity, where all stakeholders can connect and
      benefit from the expertise, knowledge and activities
      of this shared action-oriented platform.
    4. We commit to build on past experiences towards
      achieving this objective, including ensuring that
      every activity we undertake is executed through the
      lens of equitable global access, and that the voices
      of the communities most affected are heard.
    5. We commit to be accountable to the world, to
      communities, and to one another. We are coming
      together in the spirit of solidarity, and in the service
      of humanity, to achieve our mission and vision.

    Our Call

    We ask the global community and political leaders to
    support this landmark collaboration, and for donors to
    provide the necessary resources to accelerate achievement
    of the objectives of this global collaboration, capitalizing
    on the opportunity provided by the rolling pledging
    campaign that will start on 4 May 2020.

    Commitment and call to action: Global collaboration to accelerate new COVID-19 health technologies
    Read More
    https://www.who.int/news-room/detail/24-04-2020-commitment-and-call-to-action-global-collaboration-to-accelerate-new-covid-19-health-technologies

    Views: 0

  • WHO urges countries to move quickly to save lives from malaria in sub-Saharan Africa

    WHO urges countries to move quickly to save lives from malaria in sub-Saharan Africa

    Severe disruptions to insecticide-treated net campaigns and in access to antimalarial medicines could lead to a doubling in the number of malaria deaths in sub-Saharan Africa this year compared to 2018, according to a new modelling analysis released by
    WHO and partners ahead of World Malaria Day (25 April).

    WHO urges countries to move fast and distribute malaria prevention and treatment tools at this stage of the COVID-19 outbreak in sub-Saharan Africa, and to do their utmost to safely maintain these essential malaria control services.

    The analysis considers nine scenarios for potential disruptions in access to core malaria control tools during the pandemic in 41 countries, and the resulting increases that may be seen in cases and deaths. 

    Under the worst-case scenario, in which all insecticide-treated net (ITN) campaigns are suspended and there is a 75% reduction in access to effective antimalarial medicines, the estimated tally of malaria deaths in sub-Saharan Africa in 2020 would reach
    769 000, twice the number of deaths reported in the region in 2018. This would represent a return to malaria mortality levels last seen 20 years ago.

    According to the World malaria report 2019, sub-Saharan Africa accounted for approximately 93% of all malaria cases and 94% of deaths in 2018. More than two-thirds of deaths were among children under the age of five.

    A window of opportunity

    To date, the number of reported cases of COVID-19 in sub-Saharan Africa has represented only a small proportion of the global total, though cases are increasing every week. This means that countries across the region have a critical window of opportunity
    to minimize disruptions in malaria prevention and treatment and save lives at this stage of the COVID-19 outbreak.

    Mass vector control campaigns should be accelerated, while ensuring that they are deployed in ways that protect health workers and communities against potential COVID-19 transmission. WHO and partners commend the leaders of Benin, the Democratic Republic of the Congo, Sierra Leone and Chad
    for initiating ITN campaigns during the pandemic. Other countries are adapting their net distribution strategies to ensure households receive the nets as quickly and safely as possible.

    Preventive therapies for pregnant women and children must be maintained. The provision of prompt diagnostic testing and effective antimalarial medicines are also essential to prevent a mild case of malaria from progressing to severe illness and death.

    WHO and partners have developed guidance to ensure that those suffering from malaria can safely receive the care they need within the package of essential health services to be delivered in COVID-19 settings. Tailoring malaria interventions in COVID-19 response includes guidance on the prevention of infection through vector control and chemoprevention, testing, treatment of cases, clinical services, supply chain and laboratory activities.

    Note to the editor

    The modelling analysis was conducted by WHO in close collaboration with partners, including PATH, the Malaria Atlas Project and the Bill & Melinda Gates Foundation. 

    The analysis is subject to uncertainties. It does not consider, for example, the effects of an interruption in indoor residual spraying or seasonal malaria chemoprevention (except in Burkina Faso); a suspension of these core malaria prevention tools would
    also lead to considerable loss of life.

    In addition, there is limited understanding of the spread of COVID-19, its epidemiology and interactions with malaria. The model will be updated as such data become available, and countries will be provided with relevant information to tailor their responses
    accordingly.

    WHO urges countries to move quickly to save lives from malaria in sub-Saharan Africa
    Read More
    https://www.who.int/news-room/detail/23-04-2020-who-urges-countries-to-move-quickly-to-save-lives-from-malaria-in-sub-saharan-africa

    Views: 0

  • Tools for Maximizing Customer Relationships

    Business is tough these days and the economy has caused companies of all sizes to rethink when and how to nurture their relationship with customers. While it may seem like an easy decision to cut back on investing in customer marketing, that may not be the wisest choice. As products and services continue to become commoditized, the only remaining differentiator becomes the vendor‐customer relationship. There?s no getting around that delighting customers and growing revenue will become more heavily based on how well you understand their evolving needs. This article explores three categories of tools used to engage customers and strengthen your relationship with them.

    Read More
    http://www.associationofmarketing.org/whitepapers/view.php?whitepaper_id=77

    Views: 0

  • Hear Urgent Cases Via Skype, Zoom, Falana Tells Nigerian Judges

    Hear Urgent Cases Via Skype, Zoom, Falana Tells Nigerian Judges

    Hear Urgent Cases Via Skype, Zoom, Falana Tells Nigerian Judges 1

    Hear Urgent Cases Via Skype, Zoom, Falana Tells Nigerian Judges 2


    Senior Advocate of Nigeria, Femi Falana, has urged the Chief Justice of Nigeria, Ibrahim Muhammad, to prevail on judges in the country to “hear urgent applications via Skype or Zoom during the lockdown”.

    Following the outbreak of Coronavirus in Nigeria, courts were directed to shut down until the pandemic was brought under control by government.

    But encouraging judges to embrace technological tools to attend to cases during this lockdown period, Falana in a letter to the CJN said, “Since the Federal Government has relaxed the lockdown by allowing markets, shops and stalls selling food and groceries to open to customers between the hours of 10:00am and 2:00pm daily, the National Judicial Council ought to review the suspension of court sittings to enable them attend to urgent matters to ensure that thousands of people who are either awaiting trial or under investigation are not subjected to unlawful detention.

    “The review has become necessary in view of the fact that motions for the bail of many criminal suspects and applications to secure the enforcement of the fundamental right to personal liberty of other detainees are pending in several courts in all the states of the federation and in the federal capital territory.

    “In addition, the return dates in respect of several ex parte orders made by magistrates for the remand of a number of criminal suspects which have since expired are due to be quashed or renewed to extend time for further investigation.

    “More so that the heads of the various courts are vested with the power to designate judges and magistrates to attend to urgent matters in accordance with the laws establishing such courts.

    “However, in order to observe the social distancing directive, we suggest that arrangements be made for judges to hear urgent applications via Skype or Zoom.”

    Already, that strategy had been adopted in Kenya where 4,800 prisoners had been released by judges after hearing their cases through Skype and Zoom, a report by CNN said.

    “We prioritised getting a lot of people out of prison, especially petty offenders. Those who are in prison for a short term and those who have been there for a long time but have just about six months and below to go,” Anne Amadi, Chief Registrar of the judiciary in Kenya, told CNN.

    “As of Friday last week, we managed to decongest the prison by about 4800 inmates from different parts of the country. 

    “All our 39 high court stations have released people. Most of them, a good number, through Skype or Zoom,” she added.

    Legal

    PUBLIC HEALTH

    News

    AddThis

    : 

    Original Author

    : 

    SaharaReporters, New York

    Disable advertisements

    : 
    Hear Urgent Cases Via Skype, Zoom, Falana Tells Nigerian Judges
    Read More
    http://saharareporters.com/2020/04/08/hear-urgent-cases-skype-zoom-falana-tells-nigerian-judges

    Views: 0

  • WHO lists two COVID-19 tests for emergency use

    WHO has listed the first two diagnostic tests for emergency use during the Covid-19 pandemic. The move should help increase access to quality-assured, accurate tests for the disease.  It also means that the tests can now be supplied by the United
    Nations and other procurement agencies supporting the COVID-19 response.

    Both in vitro diagnostics, the tests are genesig Real-Time PCR Coronavirus (COVID-19) and cobas SARS-CoV-2 Qualitative assay for use on the cobas® 6800/8800 Systems. 

    “The emergency use listing of these products will enable countries to increase testing with quality assured diagnostics,” says Dr Mariângela Simão, WHO Assistant-Director General for Medicines and Health Products. “Facilitating
    access to accurate tests is essential for countries to address the pandemic with the best tools possible.” 

    The Emergency Use Listing procedure (EUL) was established to expedite the availability of diagnostics needed in public health emergency situations. It is intended to help procurement agencies
    and countries navigate the large presence of different devices on the market and, by assessing them, provides assurance of the products’ quality and performance.

    The genesig Real-Time PCR Coronavirus (COVID-19) (Primerdesign, United Kingdom) is an open system more suitable for laboratories with moderate sample testing capacity, while the cobas® SARS-CoV-2 for use on the cobas® 6800/8800 Systems (Roche, United States of America) is a closed system assay for larger laboratories.

     

    EUL listed products:

    https://www.who.int/diagnostics_laboratory/200407_eul_sars_cov2_product_list.pdf?ua=1

    Roche test:

    https://www.who.int/diagnostics_laboratory/eul_0504-046-00_cobas_sars_cov2_qualitative_assay_ifu.pdf?ua=1

    Primerdesign test:

    https://www.who.int/diagnostics_laboratory/eul_0489_185_00_path_covid19_ce_ivd_ifu_issue_2.0.pdf?ua=1

    Read More
    https://www.who.int/news-room/detail/07-04-2020-who-lists-two-covid-19-tests-for-emergency-use

    Views: 0